Company intelligence / Profile preview
Enveda Biosciences
Boulder, Colorado, United Statesenveda.com ↗
- Ownership
- Private
- Employees
- ~150
- Development stage
- Other
01
Overview
ENV‑294 entered Phase 1 clinical trials in late 2024 after IND clearance from the FDA. The molecule has shown JAK-inhibitor-like efficacy with improved safety profile in preclinical models of atopic dermatitis. Additional pipeline candidates are advancing toward the clinic targeting IBD and other major diseases. Clinical catalysts expected in 2025–2026.[3][5]
No published late-stage or commercial results yet.
- Therapeutic areas
- EndocrinologyImmunologyOtherDermatologyGastroenterologyNeurology
- Modalities
- Small moleculesNatural products
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Request access →Beyond the preview
Go deeper on Enveda Biosciences.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Enveda Biosciences.